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Increasing value in research 
This issue of the British Journal of Dermatology (BJD) includes a comprehensive and engaging report 
of a systematic review of randomised controlled trials of topical herbal medicines for atopic 
eczema.
1
 Thandar et al have complied with the PRISMA guidelines for reporting systematic reviews, 
as required by the BJD.
2
 They clearly explain their focus on topical herbal medicines for atopic 
eczema because there is a high level of patient interest. The authors also justify the need for this 
systematic review in order to fill a gap in existing and on-going reviews. They state the aims of their 
review; provide details about their search strategy; list their inclusion and exclusion criteria and 
provide a table of study characteristics. The risk of bias assessments are used to inform the 
discussion and the conclusions are supported by the evidence presented. The only thing missing is 
registration of a protocol.  
KŶĞŽĨƚŚĞĐĂƵƐĞƐŽĨ ?ǁĂƐƚĞ ?ŝŶƌĞƐĞĂƌĐŚŝƐ a lack of transparency in research methods, of all study 
designs.
3
 For systematic reviews, as with trials, a protocol provides details of planned methods, 
reducing risk of biases. Making a review protocol publically available was until recently almost 
impossible. Within the last five years, a number of journals have started accepting protocols for 
publication, and PROSPERO a free to search, free to register international prospective register of 
systematic reviews has been launched.
4
 Journals are now asking for the protocol registration details 
with submitted manuscripts in line with item 5 in the PRISMA checklist.
5 
However, providing 
reporting guidelines, checklists and registration facilities only helps to improve the quality of 
published research if they are adhered to by authors, peer reviewers, and editors.
6 
 
Another advantage of a single open access database of registered protocols is in helping avoid 
duplication.
7 
Thander et al were able to set their clearly specified research question in the context of 
not only existing reviews, but on-going reviews of other treatment options.  
One of the disappointing findings of the Thander et al review is that sample sizes were small, ranging 
from 12 (participants were their own controls) to 144. This is not unusual in systematic reviewing 
and highlights another potential area of waste in research. There is pressure on clinicians throughout 
their training and as part of their ongoing professional development to undertaken research. 
Funding for large projects in collaboration with academic colleagues is limited and the processes for 
research ethics and governance daunting. While it is tempting to undertake small studies, it has 
recently been demonstrated that few pilot studies, often a justification for a small sample size, are 
well reported and only 8 out of 90 pilot studies identified in an earlier review had led to a main 
study.
8
 
/ŶĐƌĞĂƐŝŶŐǀĂůƵĞĂŶĚƌĞĚƵĐŝŶŐǁĂƐƚĞŝŶƌĞƐĞĂƌĐŚŝƐŝŶĞǀĞƌǇŽŶĞ ?ƐŝŶƚĞƌĞƐƚƐĂŶĚŝƐƚŚĞ responsibility of 
authors, editors, publishers, peer reviewers and readers.  
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